Drug intelligence / Profile preview

INK713

Development stage: Preclinical
Lead developer: Infinity Pharmaceuticals
Modality: Small Molecules

Overview

INK713 is a potent and selective small molecule inhibitor of the delta (δ) and gamma (γ) isoforms of phosphoinositide 3-kinase (PI3K). Developed by Intellikine, the compound was investigated for its potential in treating B-cell malignancies, including various types of lymphoma and multiple myeloma. Preclinical data presented at the AACR 2010 meeting indicated that INK713 possesses high affinity for PI3Kδ and PI3Kγ (IC50 < 10 nM) with significant selectivity over the alpha and beta isoforms. Its mechanism of action involves the disruption of PI3K-mediated signaling pathways that drive the proliferation and survival of malignant B-cells.

Targets

PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)

Beyond the preview

Go deeper on INK713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INK713.

Explore the full profile